Evidence map›Paper›PMID 38007475›Full record

SynthesisBMC ophthalmology2023

Prevalence of age-related macular degeneration in Iran and its projections through 2050: a systematic review and meta-analysis.

Amirhossein Roshanshad, Romina Roshanshad, Seyed Ali Moosavi, Ali Ardekani, Sara Sadat Nabavizadeh, Reza Fereidooni, Hossein Ashraf, Hossein Molavi Vardanjani

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMC ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Amirhossein RoshanshadPoostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Romina RoshanshadStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Ali MoosaviStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali ArdekaniSchool of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Sara Sadat NabavizadehStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Reza FereidooniHealth Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossein AshrafPoostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossein Molavi VardanjaniMPH Department, Shiraz University of Medical Sciences, Shiraz, Iran. hosseinmolavi@ymail.com.ORCID http://orcid.org/0000-0001-7024-8894
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAge-related Macular Degeneration (AMD) is one of the most common causes of vision loss. A substantial increase in the burden of AMD is expected in the aging populations, including the Iranians. We investigated the age and gender-specific prevalence of AMD and its determinants in Iran.

methodsWe systematically searched international (PubMed, Scopus, Embase, etc.) and local (IranDoc, Magiran, etc.) online databases. We included cross-sectional or cohort studies, either clinic- or population-based, published on the prevalence of AMD among Iranians, with no limitation on age. Joanna Briggs Institute (JBI) tools for critical appraisal were used. Prevalence estimates are pooled by applying random-effects modeling. Subgroup analysis and meta-regression were performed.

resultsSeventeen studies with 16,120 participants were included. Based on studies in general population, the pooled prevalence of AMD was 10.8% (95% CI: 6.5-16.2%) in males, and 9.8% (95% CI: 4.7-16.4%) in females. 8.5% of moderate vision impaired, 13.6% of severe vision impaired, and 15.7% of blind participants were affected by AMD. The prevalence of AMD was 2% in 40-49, and 32.3% in the ≥ 80 population. The prevalence of AMD was 11.9% among the visually impaired vs. 8.7% in the general population. The study's sampling method, location, and mean age were correlated with the heterogeneities of the prevalence. We observed an increasing trend in the number of AMD cases (average annual percent change = 3.66%; 95% CI: 3.65-3.67%) from 1990 to 2050. The expected number of AMD cases in Iran will be near 5.5 million by 2050.

conclusionThe prevalence of AMD in Iran was somewhere between the prevalence of Asians and Europeans. Given the aging trend of the Iranian community and an average annual percent change of 3.66%, it is indispensable to adopt preventive and screening policies to diminish the burden of the disease in the future decades.

Indexed as

Macular DegenerationBlindnessCross-Sectional StudiesFemaleHumansIranMalePrevalenceAMDEpidemiologyIranMacular DegenerationMiddle EastPrevalence

Identifiers

PMID38007475
PMCPMC10675929
OpenAlexW4388998689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.